✦ LIBER ✦

Clinical studies with low-molecular-weight heparin(oid)s: An interim analysis

✍ Scribed by Dr. Hugo Ten Gate; C. Pieter Henny; Jan W. Ten Cate; Harry R. Büller

Publisher: John Wiley and Sons
Year: 1988
Tongue: English
Weight: 838 KB
Volume: 27
Category: Article
ISSN: 0361-8609
DOI: 10.1002/ajh.2830270217

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinically significant thromboembolic di

Clinically significant thromboembolic disease in orthopedic oncology: An analysis of 986 patients treated with low-molecular-weight heparin

✍ Pietro Ruggieri; Maurizio Montalti; Elisa Pala; Andrea Angelini; Teresa Calabrò; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

Clinically significant thromboembolic di

Clinically significant thromboembolic disease in orthopedic oncology: An analysis of 986 patients treated with low molecular-weight heparin

✍ Thomas Scharschmidt 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 44 KB

Prospective randomized clinical study in

Prospective randomized clinical study in general surgery comparing a new low molecular weight heparin with unfractionated heparin in the prevention of thrombosis

✍ Limmer, J. ;Ellbr�ck, D. ;M�ller, H. ;Eisele, E. ;Rist, J. ;Sch�tze, F. ;Beger, 📂 Article 📅 1994 🏛 Springer-Verlag 🌐 English ⚖ 614 KB

Cost-minimization analysis of low-molecu

Cost-minimization analysis of low-molecular-weight heparin (dalteparin) compared to unfractionated heparin for inpatient treatment of cancer patients with deep venous thrombosis

✍ Elenir B. C. Avritscher; Scott B. Cantor; Ya-Chen T. Shih; Carmelita P. Escalant 📂 Article 📅 2004 🏛 Springer-Verlag 🌐 English ⚖ 154 KB

Dextran's antithrombotic properties in s

Dextran's antithrombotic properties in small arteries are not altered by low-molecular-weight heparin or the fibrinolytic inhibitor tranexamic acid: An experimental study

✍ Baimeng Zhang; Jan B. Wieslander 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 576 KB

## Abstract In two separate blind, randomized studies, 48 rabbits were divided into five groups. Three treated groups received dextran 70 (0.51 g/kg) as a single injection, dextran 70 combined with low molecular‐weight heparin (LMWH) (560 IU/kg as anti‐FXa and 140 IU/kg as APTT in 3 hr), and dextra

Local and systemic delivery of low molec

Local and systemic delivery of low molecular weight heparin following PTCA: Acute results and 6-month follow-up of the initial clinical experience with the porous balloon (PILOT-study)

✍ Oberhoff, Martin ;Baumbach, Andreas ;Hermann, Thomas ;Diehl, Claudia ;Maier, Rit 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB 👁 2 views

The purpose of this study was to assess safety and feasibility of intracoronary delivery of reviparin using a porous balloon following percutaneous transluminal coronary angioplasty. The 2.7 mm porous balloon used in this study had 35 holes arranged in a spiral pattern. Eighteen patients (male n ‫؍